Biological Assembly 1  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 26.04 kDa 
• Atom Count: 1803 
• Modelled Residue Count: 223 
• Deposited Residue Count: 243 
• Unique protein chains: 1

1F0U

BOVINE TRYPSIN COMPLEXED WITH RPR128515

• PDB DOI: 10.2210/pdb1F0U/pdb

• Classification: HYDROLASE
• Organism(s): Bos taurus
• Mutation(s): No 


• Deposited: 2000-05-17 Released: 2000-09-20 
• Deposition Author(s): Maignan, S., Guilloteau, J.P., Pouzieux, S., Choi-Sledeski, Y.M., Becker, M.R., Klein, S.I., Ewing, W.R., Pauls, H.W., Spada, A.P., Mikol, V.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Work: 0.172 
• R-Value Observed: 0.172 

Literature

Crystal structures of human factor Xa complexed with potent inhibitors.

Maignan, S., Guilloteau, J.P., Pouzieux, S., Choi-Sledeski, Y.M., Becker, M.R., Klein, S.I., Ewing, W.R., Pauls, H.W., Spada, A.P., Mikol, V.

(2000) J Med Chem 43: 3226-3232

• PubMed: 10966741 
• DOI: 10.1021/jm000940u
• Primary Citation of Related Structures:  
  1EZQ, 1F0R, 1F0S, 1F0T, 1F0U


• PubMed Abstract: 
  

Involved in the coagulation cascade, factor Xa (FXa) is a serine protease which has received great interest as a potential target for the development of new antithrombotics. Although there is a great wealth of structural data on thrombin complexes, few structures of ligand/FXa complexes have been reported, presumably because of the difficulty in growing crystals. Reproducible crystallization conditions for human des-Gla1-45 coagulation FXa have been found. This has led to an improvement in the diffraction quality of the crystals (about 2.1 A) when compared to the previously reported forms (2.3-2.8 A) thus providing a suitable platform for a structure-based drug design approach. A series of crystal structures of noncovalent inhibitors complexed with FXa have been determined, three of which are presented herein. These include compounds containing the benzamidine moiety and surrogates of the basic group. The benzamidine-containing compound binds in a canonical fashion typical of synthetic serine protease inhibitors. On the contrary, molecules that contain surrogates of the benzamidine group do not make direct hydrogen-bonding interactions with the carboxylate of Asp189 at the bottom of the S1 pocket. The structural data provide a likely explanation for the specificity of these inhibitors and a great aid in the design of bioavailable potent FXa inhibitors.

---

Organizational Affiliation: 

Department of Structural Biology, Aventis Pharma, 13, Quai J. Guesde, F-94403 Vitry/Seine, France.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
TRYPSIN	A	243	Bos taurus	Mutation(s): 0  EC: 3.4.21.4
UniProt
Find proteins for P00760 (Bos taurus) Explore P00760  Go to UniProtKB:  P00760

Small Molecules

Ligands 3 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
RPR	D [auth A]	3-[(3'-AMINOMETHYL-BIPHENYL-4-CARBONYL)-AMINO]-2-(3-CARBAMIMIDOYL-BENZYL)-BUTYRIC ACID METHYL ESTER C27 H30 N4 O3 XFKVLKLCLYJKNF-MZNJEOGPSA-N
SO4	C [auth A]	SULFATE ION O4 S QAOWNCQODCNURD-UHFFFAOYSA-L
CA	B [auth A]	CALCIUM ION Ca BHPQYMZQTOCNFJ-UHFFFAOYSA-N

Binding Affinity Annotations
ID	Source	Binding Affinity
RPR	PDBBind:  1F0U	Ki: 69 (nM) from 1 assay(s)
	BindingDB:  1F0U	Ki: 69 (nM) from 1 assay(s)
	Binding MOAD:  1F0U	Ki: 69 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Work: 0.172 
• R-Value Observed: 0.172 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 63.73	α = 90
b = 63.89	β = 90
c = 69.17	γ = 90

Software Package:

Software Name	Purpose
DENZO	data reduction
SCALEPACK	data scaling
AMoRE	phasing
X-PLOR	refinement

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2000-05-17 
• Released Date: 2000-09-20 
Deposition Author(s): Maignan, S., Guilloteau, J.P., Pouzieux, S., Choi-Sledeski, Y.M., Becker, M.R., Klein, S.I., Ewing, W.R., Pauls, H.W., Spada, A.P., Mikol, V.

Revision History  

• Version 1.0: 2000-09-20
  Type: Initial release
  
• Version 1.1: 2008-04-27
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Version format compliance